The Usefulness of Nanotechnology in Improving the Prognosis of Lung Cancer

Abstract

Lung cancer remains a major public health problem both in terms of incidence and specific mortality despite recent developments in terms of prevention, such as smoking reduction policies and clinical management advances. Better lung cancer prognosis could be achieved by early and accurate diagnosis and improved therapeutic interventions. Nanotechnology is a dynamic and fast-developing field; various medical applications have been developed and deployed, and more exist as proofs of concepts or experimental models. We aim to summarize current knowledge relevant to the use of nanotechnology in lung cancer management. Starting from the chemical structure-based classification of nanoparticles, we identify and review various practical implementations roughly organized as diagnostic or therapeutic in scope, ranging from innovative contrast agents to targeted drug carriers. Available data are presented starting with standards of practice and moving to highly experimental methods and proofs of concept; particularities, advantages, limits and future directions are explored, focusing on the potential impact on lung cancer clinical prognosis.

Tumor-derived extracellular vesicle drug delivery system for chemo-photothermal-immune combination cancer treatment

“…Patients with early breast cancer neoadjuvant treatment and lung squamous cell carcinoma had a higher rate of full remission and overall survival than with standard paclitaxel. 5 In comparison to paclitaxel, albumin is an endogenous product of the human body. It can employ the albumin receptor Gp60 on the cell membrane and the role of cysteine-rich acidic secretory protein (SPARC) in tumor tissue to improve drug entry and increase chemotherapy efficacy.…”

“…It outperforms conventional paclitaxel in terms of the full remission rate and overall survival in patients with early stage breast cancer and lung squamous cell carcinoma who received neoadjuvant therapy. 5 However, the overall treatment effect remains non-ideal, and the safety of the treatment, which may be related to systemic toxicity caused by PA, clearance of nano-drugs by the reticuloendothelial and complement systems, tumor accumulation, and insufficient penetration, must be improved. Therefore, designing and developing drug delivery techniques that limit systemic toxicity while improving tumor targeting can improve the therapeutic efficacy and survival status of patients with breast cancer.…”

Developments in Nanotechnology for Lung Cancer Treatment: A Comprehensive Strategy

“…A liposome's structure consists of an aqueous core, cholesterol, and phospholipids. The US FDA approved Doxil, the first formulation of Nano liposomes containing doxorubicin, in 1995 to treat Kaposi's sarcoma associated with AIDS [39]. Additionally, nanoliposomes may extend the medication's circulation, improve the stability of the integrated drug in vivo, and easily alter the size and surface of the drug to raise its therapeutic index.…”